Barinthus Biotherapeutics Plc (BRNS) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The study “Efficacy of VTP-300 in Chronic Hepatitis B Infection” tests a new combo approach for long-term control of hepatitis B. Its goal is to see if Barinthus Biotherapeutics’ VTP-300, paired with low-dose nivolumab, can safely reduce the virus in patients already on standard oral drugs, a key step toward a functional cure market.
The treatment uses two therapeutic vaccines, ChAdOx1-HBV and MVA-HBV, together branded as VTP-300. These are designed to train the immune system to better attack hepatitis B, while nivolumab is added at low dose to boost this response and possibly deepen viral control.
The trial is a phase 2b interventional study in adults with chronic hepatitis B. Patients are randomly assigned in equal groups to three dosing schedules, there is no placebo, no blinding, and the core aim is treatment benefit, focusing on how well the regimen works and how well it is tolerated over time.
The study was first submitted on April 12, 2022, marking its formal launch in the clinic. Status is now listed as completed, and the latest update on April 29, 2026 signals that Barinthus has refreshed trial information, often a prelude to data disclosure or alignment with upcoming scientific or corporate events.
For investors, completion of this phase 2b study is a key milestone for Barinthus Biotherapeutics (BRNS) as it moves VTP-300 closer to proof of concept. Positive data could support partnerships or a value re-rating, while any safety or efficacy concerns may weigh on sentiment, especially versus larger hepatitis B players like Gilead and Johnson & Johnson.
The broader hepatitis B field is competitive but still open, and a vaccine-based functional cure could create a differentiated niche if results are strong. The recent update confirms the study is completed and information is current, with more details available on the ClinicalTrials.gov portal.
To learn more about BRNS’s potential, visit the Barinthus Biotherapeutics Plc drug pipeline page.